Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin–Beck Disease Treatment
Rapid Communications in Mass Spectrometry · 2025
DOI: 10.1002/rcm.10130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Jinfeng Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Health Science Center, Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Co…. Hauptthemen laut MEDLINE: Ibuprofen, Chondroitin Sulfates, Vitamins, Kashin-Beck Disease. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Kashin–Beck disease (KBD) is an osteoarthropathy with no specific drug treatment. This study seeks to uncover the molecular mechanisms of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) in treating KBD.
Methods
Integrated transcriptomic and metabolomic analyses were performed on peripheral blood samples collected from four KBD patients before and 1 month after treatment. Differential gene expression was assessed using the DESeq package, while differential metabolites were identified through univariate and multivariate statistical analyses.
Results
After treatment, 5671 differential genes (|log 2 FC| ≥ 1, q < 0.05) were identified, with 4954 upregulated and 717 downregulated. Enriched pathways included PI3K‐Akt, MAPK, ECM‐receptor interaction, Rap1, and Ras signaling. Untargeted metabolomics analyses revealed five differentially expressed metabolites (VIP ≥ 1, |log 2 FC| > 0.58, p < 0.05): L‐glutamine, 2‐methylpropan‐2‐amine, epsilon‐caprolactam, phosphocholine, and 1‐palmitoyl‐2‐linoleoyl‐sn‐glycero‐3‐phosphocholine. Metabolite enrichment analysis suggested alterations in amino acid and fatty acid metabolism. Integrated analysis revealed key pathways such as alanine, aspartate, and glutamate metabolism and arginine biosynthesis.
Conclusions
The combination of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) may alleviate KBD through modulation of key genes (GDNF, BDNF, CCL2, VEGFA, and PPARG) and glutamine‐related metabolic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Health Science Center, Xi'an Jiaotong University, Key Laboratory of Environmental and Endemic Diseases of National Health Commission of the People's Republic of China, Xi'an, Shaanxi, China.
- Sichuan Provincial People's Hospital East Sichuan Hospital and Dazhou First People's Hospital, Dazhou, China.
- Shaanxi Provincial Center for Disease Prevention and Control, Xi'an, Shaanxi, China.
- Department of Disease Prevention and Control, Lintong Rehabilitation and Convalescent Centre, Xi'an, Shaanxi, China.
ORCID-Profile: Jinfeng Wen
Förderung
- National Key Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
Wen, J., Deng, X., Yang, Z., Niu, H., Zhang, Q., Zhao, Y., Naren, G., Liu, H., Zhang, F., Yang, X., & Wu, C. (2025). Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin–Beck Disease Treatment. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10130
Vancouver
Wen J, Deng X, Yang Z, Niu H, Zhang Q, Zhao Y, et al. Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin–Beck Disease Treatment. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10130
BibTeX
@article{Wen2025,
author = {Wen, Jinfeng and Deng, Xingxing and Yang, Zhengjun and Niu, Hui and Zhang, Qian and Zhao, Yijun and Naren, Gaowa and Liu, Huan and Zhang, Feng and Yang, Xiaodong and Wu, Cuiyan},
title = {Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin–Beck Disease Treatment},
journal = {Rapid Communications in Mass Spectrometry},
year = {2025},
doi = {10.1002/rcm.10130}
}
EUVIMED